ArticleThe Journal of international medical research2026
Metastasis-associated protein 1 rewires prostate cancer transcriptomes via direct RNA interactions governing gene expression and alternative splicing.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study investigated whether metastasis-associated protein 1 (MTA1) acts as an RNA-binding protein to directly regulate gene expression and alternative splicing in prostate cancer, thereby exploring its dual transcriptional and post-transcriptional roles.MethodsMTA1-stable-knockdown PC-3 cells were subjected to RNA sequencing and formaldehyde RNA immunoprecipitation sequencing to characterize the MTA1-RNA interactome and its functional significance.ResultsMTA1 knockdown dysregulated 1248 genes and 2367 alternative splicing events. Differentially expressed genes were enriched in extracellular matrix remodeling, PI3K-Akt signaling, and hypoxia-response pathways, whereas alternatively spliced genes were associated with spliceosome and RNA-processing pathways. Formaldehyde RNA immunoprecipitation sequencing confirmed MTA1 binding to GC-rich RNA motifs, with significant overlap between MTA1-bound targets and dysregulated genes or splicing events. Representative findings included MTA1 binding to the 3' untranslated region of COL6A1, resulting in its downregulation, and regulation of SNHG17 splicing, indicating direct roles in RNA stability and splicing regulation.ConclusionMTA1 functions as both an epigenetic modulator and an RNA-binding protein in prostate cancer, directly regulating RNA networks that promote tumor progression. These findings reveal novel RNA-mediated oncogenic mechanisms and highlight the therapeutic potential of MTA1 in prostate cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.